DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - NYSE:DOCS - US26622P1075 - Common Stock
65.82 USD
-1.13 (-1.69%)
65.82 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to DOCS. DOCS was compared to 35 industry peers in the Health Care Technology industry. DOCS gets an excellent profitability rating and is at the same time showing great financial health properties. DOCS is valued quite expensively, but it does show have an excellent growth rating. These ratings would make DOCS suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
DOCS had a positive operating cash flow in the past year.
In the past 5 years DOCS has always been profitable.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 19.52%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Equity of DOCS (22.93%) is better than 100.00% of its industry peers.
DOCS has a better Return On Invested Capital (18.77%) than 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 6.84%.
The 3 year average ROIC (14.17%) for DOCS is below the current ROIC(18.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.52% | ||
| ROE | 22.93% | ||
| ROIC | 18.77% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
With an excellent Profit Margin value of 39.88%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
Looking at the Operating Margin, with a value of 40.46%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of DOCS has grown nicely.
DOCS's Gross Margin of 90.14% is amongst the best of the industry. DOCS outperforms 97.14% of its industry peers.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.46% | ||
| PM (TTM) | 39.88% | ||
| GM | 90.14% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DOCS is creating value.
Compared to 1 year ago, DOCS has more shares outstanding
Compared to 5 years ago, DOCS has more shares outstanding
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
DOCS has an Altman-Z score of 44.22. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 44.22, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 44.22 |
ROIC/WACC1.89
WACC9.93%
2.3 Liquidity
DOCS has a Current Ratio of 6.47. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
DOCS's Current ratio of 6.47 is amongst the best of the industry. DOCS outperforms 94.29% of its industry peers.
A Quick Ratio of 6.47 indicates that DOCS has no problem at all paying its short term obligations.
The Quick ratio of DOCS (6.47) is better than 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.47 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.27%, which is quite impressive.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
DOCS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.45%.
Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 37.42% on average per year.
EPS 1Y (TTM)43.27%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%28.57%
Revenue 1Y (TTM)19.45%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%15.19%
3.2 Future
DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.47% yearly.
Based on estimates for the next years, DOCS will show a quite strong growth in Revenue. The Revenue will grow by 11.87% on average per year.
EPS Next Y9.67%
EPS Next 2Y9.88%
EPS Next 3Y11.18%
EPS Next 5Y13.47%
Revenue Next Year11.96%
Revenue Next 2Y11.43%
Revenue Next 3Y11.14%
Revenue Next 5Y11.87%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
DOCS is valuated quite expensively with a Price/Earnings ratio of 44.17.
Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than the industry average as 71.43% of the companies are valued more expensively.
DOCS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.03.
The Price/Forward Earnings ratio is 38.66, which means the current valuation is very expensive for DOCS.
Based on the Price/Forward Earnings ratio, DOCS is valued a bit cheaper than the industry average as 62.86% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of DOCS to the average of the S&P500 Index (22.27), we can say DOCS is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.17 | ||
| Fwd PE | 38.66 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DOCS is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 62.86% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.9 | ||
| EV/EBITDA | 44.08 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.57
PEG (5Y)0.56
EPS Next 2Y9.88%
EPS Next 3Y11.18%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
65.82
-1.13 (-1.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners90.54%
Inst Owner Change1.04%
Ins Owners1.94%
Ins Owner Change-0.09%
Market Cap12.33B
Revenue(TTM)589.64M
Net Income(TTM)235.13M
Analysts76.15
Price Target72.99 (10.89%)
Short Float %3.45%
Short Ratio3.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.11%
Min EPS beat(2)17.55%
Max EPS beat(2)36.67%
EPS beat(4)4
Avg EPS beat(4)25.17%
Min EPS beat(4)15.86%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)24.03%
EPS beat(12)12
Avg EPS beat(12)21.73%
EPS beat(16)16
Avg EPS beat(16)33.54%
Revenue beat(2)2
Avg Revenue beat(2)1.95%
Min Revenue beat(2)1.38%
Max Revenue beat(2)2.52%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.34%
Revenue beat(12)9
Avg Revenue beat(12)2.13%
Revenue beat(16)12
Avg Revenue beat(16)2.76%
PT rev (1m)3.54%
PT rev (3m)13.08%
EPS NQ rev (1m)0.68%
EPS NQ rev (3m)11.59%
EPS NY rev (1m)0.16%
EPS NY rev (3m)7.01%
Revenue NQ rev (1m)0.46%
Revenue NQ rev (3m)4.93%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)1.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.17 | ||
| Fwd PE | 38.66 | ||
| P/S | 20.91 | ||
| P/FCF | 42.9 | ||
| P/OCF | 41.91 | ||
| P/B | 12.02 | ||
| P/tB | 13.18 | ||
| EV/EBITDA | 44.08 |
EPS(TTM)1.49
EY2.26%
EPS(NY)1.7
Fwd EY2.59%
FCF(TTM)1.53
FCFY2.33%
OCF(TTM)1.57
OCFY2.39%
SpS3.15
BVpS5.48
TBVpS5
PEG (NY)4.57
PEG (5Y)0.56
Graham Number13.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.52% | ||
| ROE | 22.93% | ||
| ROCE | 22.84% | ||
| ROIC | 18.77% | ||
| ROICexc | 96.31% | ||
| ROICexgc | 172.66% | ||
| OM | 40.46% | ||
| PM (TTM) | 39.88% | ||
| GM | 90.14% | ||
| FCFM | 48.73% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 62.32% | ||
| Cap/Sales | 1.15% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.9% | ||
| Profit Quality | 122.2% | ||
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.47 | ||
| Altman-Z | 44.22 |
F-Score8
WACC9.93%
ROIC/WACC1.89
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)43.27%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%28.57%
EPS Next Y9.67%
EPS Next 2Y9.88%
EPS Next 3Y11.18%
EPS Next 5Y13.47%
Revenue 1Y (TTM)19.45%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%15.19%
Revenue Next Year11.96%
Revenue Next 2Y11.43%
Revenue Next 3Y11.14%
Revenue Next 5Y11.87%
EBIT growth 1Y26.79%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year15.19%
EBIT Next 3Y13.36%
EBIT Next 5Y12.98%
FCF growth 1Y54.23%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y53.19%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
Can you provide the valuation status for DOXIMITY INC-CLASS A?
ChartMill assigns a valuation rating of 3 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Overvalued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 9.67% in the next year.